The results of Bharat Biotech's third trial of the covaxin vaccine will be public soon. As part of the ongoing third trial in various hospitals of the country, the single-dose work has been completed. Also, a second dose has also been given to 80 percent of the people.
Bharat Biotech Kovaxin Phase III results may be public before February 10
After giving the second dose to all these people by the end of this month, it may take a week to review the results. It is believed that these results can be released by next February 10.
Corona vaccination has started in the country on 16 January. The Indian government has allowed the withdrawal covaxin to be used in an emergency but will continue to monitor the vaccine with it.
Several types of questions are also being raised when the vaccine is allowed to be used during the trial. The registration of the vaccine was to be completed by 30 December in Delhi, but it was extended to 4 January, as AIIMS did not get people to be included in the trial.
The company will get data by February 5
A doctor from Delhi AIIMS, who is associated with the vaccine test, told that a dose course has been completed under the third test here. While more than half the people have been given the second dose. By February 4, everyone will get a second dose. After which the data will be sent to the company by 5 February.
Kovishield is getting preference
It is claimed that 25000 people in the country are being vaccinated day after day. Statistics from states found between 16 and 21 January show that health workers are relying on Kovishield more than Kovaxin.
According to these figures, 33 percent of health workers have been vaccinated in the country's capital Delhi, 33 in Chennai, 47 in Chennai, 31 in Mumbai, 47 in Pune, 49 in Patna, 49 in Jaipur, 35 in Ahmedabad, and 42 in Hyderabad. That too when they do not have the right to select vaccines.
It Will be more than 50 percent effective
A senior vaccination official says that after considering the first two-stage test, he is confident that the vaccine's effect will be more than 50 percent. Some officials of the Ministry itself say that if less than 50 percent is found then the government does not have the strategy ahead.
First phase trials were published in Lescent
India's indigenous vaccine against the coronavirus is up to 90 percent effective. Antibodies have been found in between 81 and 91% of those tested under the first phase. According to the study published in the journal The Lascent, the Bharat Biotech vaccine has been found to be safe and effective in the first phase of testing.
According to the study, Hyderabad-based Bharat Biotech Company conducted the first test at 11 centers. Four groups were formed, accepting the application of 375 people. 100–100 in three groups and 75 in one group. A serious matter had come to the fore but later there was no problem. Among 100 people, 87.9, 91.9 and 82.8 percent have been affected.